Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μl

AIDS

Volumn 24, Issue 17, 2010, Pages 2750-2753

  Krentz, Hartmut B ^a,b   Gill, John ^a,b  

^a Sheldon M Chumir Health Centre   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL CARE; PATIENT CARE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; TIME FACTORS;

EID: 78349312875     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833f9e1d     Document Type: Article

References (16)

1. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al. Prognosis of HIV-1 infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197.
2. Battegay M, Fehr J, Fluckiger U, Elzi F. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrobial Chemotherapy 2008; 62:41-44.
3. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans SG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20:2371-2379.
4. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active anti-retroviral therapy: update of and responses to highly active antiretroviral therapy. AIDS 2004; 18:2145-2151.
5. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, et al. Causes ofdeath in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS2004; 18:2333-2337.
6. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis ofHIV-1 infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
7. Castilla J, Sobrino P, De La Feunte L, Noquer I, Gureea L, Parras F, et al. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS inci-dence. AIDS 2002; 16:1945-1951.
8. Girardi E, Arici C, Ferrara M, Ripamonti D, Aloisi M, Alessan-drini A, et al. Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation. AIDS 2001; 15:2201-2203.
9. Girardi E,Sabin CA. d'Armino Monfortealatediagnosis of HIV infection: epidemiological features, consequences, and strate-gies to encourage earlier testing.JAcquir Immune Defic Syndr 2007; 46:S3-S8.
10. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009; 21:284-293.
11. Krentz HB, Auld C, Gill MJ. The high cost of medical care for patients who present late with HIV infection. HIVMed 2004; 5:93-98.
12. Levy A, James D, Johnston KM, Hoggs RS, Harrigan RR, Harri-gan BP, et al. Thedirectcostof HIV/AIDScare. Lancet Infec Dis 2006; 6:171-177.
13. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIVMedicine 2008; 9:721-730.
14. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Cost of HIV medical care in the era of highly active anti-retroviral therapy. AIDS 1999; 13:963-969.
15. Bozzette SA, Joyce G, McCaffery DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Eng J Med 2001; 344:817-831.
16. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revisedrecommendations for HIVofadults, adolescent and pregnant women in healthcare settings. MMWR Recomm Rep 2006; 55:1-17.